Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Krystal Biotech (KRYS) Other Gross PP&E Adjustments (2020 - 2026)

Krystal Biotech's Other Gross PP&E Adjustments history spans 7 years, with the latest figure at $176.0 million for Q1 2026.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 7.72% to $176.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $176.0 million, a 7.72% increase, with the full-year FY2025 number at $168.9 million, up 4.43% from a year prior.
  • Other Gross PP&E Adjustments hit $176.0 million in Q1 2026 for Krystal Biotech, up from $168.9 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for KRYS hit a ceiling of $176.0 million in Q1 2026 and a floor of $129.0 million in Q1 2022.
  • Historically, Other Gross PP&E Adjustments has averaged $160.2 million across 5 years, with a median of $163.4 million in 2025.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 298.23% in 2022 and later fell 2.07% in 2025.
  • Tracing KRYS's Other Gross PP&E Adjustments over 5 years: stood at $153.0 million in 2022, then grew by 4.31% to $159.6 million in 2023, then increased by 1.34% to $161.7 million in 2024, then increased by 4.43% to $168.9 million in 2025, then rose by 4.2% to $176.0 million in 2026.
  • Business Quant data shows Other Gross PP&E Adjustments for KRYS at $176.0 million in Q1 2026, $168.9 million in Q4 2025, and $164.2 million in Q3 2025.